Mostrar el registro sencillo del ítem
dc.contributor.author | Montes, Maria Luisa | |
dc.contributor.author | Busca, Carmen | |
dc.contributor.author | Espinosa, Nuria | |
dc.contributor.author | Bernardino, José Ignacio | |
dc.contributor.author | Ibarra-Ugarte, Sofia | |
dc.contributor.author | Martín-Carbonero, Luz | |
dc.contributor.author | Moreno-Prieto, Cristina | |
dc.contributor.author | Macias, Juan | |
dc.contributor.author | Rivero, Antonio | |
dc.contributor.author | Cervero-Jiménez, Miguel | |
dc.contributor.author | González-García, Juan | |
dc.contributor.author | CoRIS | |
dc.date.accessioned | 2024-05-13T09:22:33Z | |
dc.date.available | 2024-05-13T09:22:33Z | |
dc.date.issued | 2024-04 | |
dc.identifier.citation | Open Forum Infect Dis. 2024 Mar 1;11(4):ofae112. | es_ES |
dc.identifier.issn | 2328-8957 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19374 | |
dc.description.abstract | Objective: The incidence of type 2 diabetes mellitus (T2DM) has risen dramatically. Among people living with HIV (PLHIV), chronic disease (now >15 cases/1000 in the general population worldwide) and long-term exposure to antiretroviral therapy (ART) can alter metabolic processes early, favoring insulin resistance and T2DM. We retrospectively studied the incidence of T2DM and associated factors in the Cohort of the Spanish AIDS Research Network, a prospective cohort of PLHIV enrolled at diagnosis and before initiation of ART. Methods: PLHIV were aged >18 years and ART naive at inclusion. The incidence of new diagnoses of T2DM after initiation of ART (per 1000 person-years) was calculated. Predictors of a diagnosis of T2DM were identified by a Cox proportional hazards model adjusted for statistically significant and clinically relevant variables. Results: Cumulative incidence was 5.9 (95% CI, 5.1-6.7) per 1000 person-years, increasing significantly in persons aged >50 years to 14.4 (95% CI, 10.4-19.3). Median time to diagnosis of T2DM was 27 months. Only age and higher education were significant. Interestingly, higher education was associated with a 33% reduction in the incidence of T2DM. Having received tenofovir disoproxil fumarate + (lamivudine or emtricitabine) + rilpivirine was almost significant as a protective factor (hazard ratio, 0.49; 95% CI, .24-1.01; P = .05). Conclusions: The incidence of T2DM in PLHIV in Spain was high, especially in persons aged >50 years. Age was the factor most closely associated with onset, and educational level was the factor most associated with reduced risk. We highlight the lack of association between HIV-related factors and T2DM and show that, within nonnucleoside reverse transcriptase inhibitors, rilpivirine could prove more benign for metabolic comorbidities. | es_ES |
dc.description.sponsorship | This work was supported by the Ministerio de Sanidad (RD12/0017/0012), integrated in the Plan Nacional de I + D + I and cofunded by the ISCIII-Subdirección General de Evaluación; the Fondo Europeo de Desarrollo Regional (project PI18/011270), funded by Instituto de Salud Carlos III and cofunded by the European Union; CIBER (Consorcio Centro de Investigación Biomédica en Red; CB2021); the Instituto de Salud Carlos III; the Ministerio de Ciencia e Innovación; the Unión Europea-NextGenerationEU; and the Cohort of the Spanish HIV/AIDS Research Network, funded by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en SIDA (RIS C03/173, RD12/0017/0018, and RD16/0002/0006) as part of the Plan Nacional R + D + I and cofunded by the ISCIII Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | DM2 | es_ES |
dc.subject | Incidence | es_ES |
dc.subject | Treatment naive | es_ES |
dc.subject | ART | es_ES |
dc.subject | Rilpivirine | es_ES |
dc.title | Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38560607 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | ofae112 | es_ES |
dc.identifier.doi | 10.1093/ofid/ofae112 | es_ES |
dc.contributor.funder | Ministerio de Sanidad (España) | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. NextGenerationEU | es_ES |
dc.contributor.funder | RETICS-Sida (RIS-ISCIII) (España) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1093/ofid/ofae112 | es_ES |
dc.identifier.journal | Open forum infectious diseases | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI18/011270 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0012/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD12/0017/0018 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0002/0006 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RISC03/173 | es_ES |